Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists Specializing in Hematologic Malignancies in the U.S.

Articles with lock require a subscription to GLG News | Request a free trial
January 9, 2008
Tanespimycin: A potential player in treatment of MM and other hematological malignancies
Analysis of: Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma | www.pipelinereview.com
Author: GLG Expert Contributor
Kosan's Bioscience is investigating if its Hsp-90 inhibvitor,  Tanespimycin can improve on the efficacy of Velcade ( Millenium) in patients with Multiple Myeloma (MM) in first relapse. TIME-1 trial is well designed and well powered to test the primary endpoint of prolonging the PFS by ~ 3...
December 31, 2007
IL-21 More Biologic Fodder for Melanoma
Analysis of: ZymoGenetics Begins Phase 2 Clinical Trial of IL-21 in Melanoma | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
IL-21 is a cytokine with biological activity in regulating cytotoxic T cells and natural killer cells.   In phase I studies, some tumor reduction was observed in patients with melanoma.  The current phase II trial will be designed to assess kidvid and toxicity in patients with metastatic...
December 28, 2007
TLR9 Agonists Intriguing If Cytokines Treat Cancer
Analysis of: Merck KGaA and Idera Pharmaceuticals to Collaborate on Development of TLR9 Agonists for Treatment of Cancer | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
TLR9 agonists have the potential to trigger the release of cytokines including interferon alfa.  IMO-2055 is a TLR9 agonist currently undergoing trials in combination with Tarceva and Avastin in patients with advanced non-small cell lung cancer and at two dose levels in a Phase IIa trial in patients...
December 28, 2007
IPI-504: Potential Activity But Limited Data
Analysis of: Infinity and MedImmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor's Potential Anti-Tumor Activity in Patients With Advanced Non-Small Cell Lung Cancer | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
IPI-504 is an HSP90 inhibitor with activity against cancer.  A phase I/II trial has been initiated to assess the activity of this agent in groups of patients with both EGFR mutation positive and negative tumors.  Preliminary results are available from the phase I portion of the trial...
December 28, 2007
Avastin Approved in Europe for Renal Cell Carcinoma- Is it Better than Sutent?
Analysis of: Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Avastin now has been approved in Europe for the treatment of metastatic renal cell carcinoma.  However, available data leave questions as to why this agent should be favored over Sutent.
December 20, 2007
Sutent's cardiac toxicity is real and will decrease its use
Analysis of: Targeted cancer drug poses heart risk | www.philly.com
Author: GLG Expert Contributor
Pfizer's sutent cased moderate to severe cardiac toxicity in a study involving 75 patients who all had normal cardiac function at study entry. This relatively high rate of adverse events will push physicians more towards prescribing Nexavar ( Bayer/Onyx)  and Torisel (Wyeth) in patients...
December 17, 2007
Telomerase vaccine: Promising , but main role is in minimal residual disease
Analysis of: Geron receives milestone payment from merck triggered by ind filing for telomerase cancer vaccine candidate | www.pipelinereview.com
Author: GLG Expert Contributor
Geron's cancer vaccine targets telomerase which is active in growth of many cancers. Eraly clinical trials are ongoing in AML and vaccine may have role in melanoma, sarcomas, NHL and lung cancer. Main role of cancer vaccines is in minimal residual disaese or as maintenanence/consolidation therapy...
Taral PatelDecember 7, 2007
Avastin in breast cancer
Analysis of: F.D.A. Criticizes Avastin Use for Breast Cancer | www.nytimes.com
Author: Taral Patel, Oncologist, Mid Ohio Oncology Hematology Inc.
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...
December 6, 2007
DDAVP : New warnings will impact use in Nocturnal Enuresis
Analysis of: Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) | www.fda.gov
Author: GLG Expert Contributor
FDA issued warnings about severe hyponatremia and seizures associated with intranasal use of desmopressin ( DDAVP, Stimate) and cautioned against prescription for primary nocturnal enuresis- a usually large indication. DDAVP use will be now  limited to treatment of homeostasis disorders  ...
December 4, 2007
Topical Valproic acid has efficacy but the main treatment is still surgical
Analysis of: TopoTarget Announces Encouraging Clinical Results from Phase II Trial of Topical BACECA (R) in Combination with Retinoid for the Treatment of the Skin Cancer Basal Cell Carcinoma | www.pipelinereview.com
Author: GLG Expert Contributor
Topotarget's  Baceca ( a topical form of Valproic acid) improved on the efficacy of topical retinoids in treatment of basal cell carcinoma. The main treatment of basal cell carcinoma is surgical or electrocauterization or laser. Topical therapy is limited to cases not amenable to above curative...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 337

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617